Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Frank Yeh

Gastroenterology Vancouver, WA Medical Doctor

NPI 1710102959 CMS profile 258707

3250 Se 164Th Ave Ste 205, Vancouver, WA 98683

Open in the dashboard

General payments

$9,904

478 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Frank Yeh of Vancouver, WA is reported in the CMS Open Payments database as having received $9,904 across 478 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $699 19
2024 General $628 9
2023 General $1,722 67
2022 General $2,002 107
2021 General $1,733 93
2020 General $948 56
2019 General $2,173 127

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frank Yeh
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Frank Yeh were reported at $699. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Frank Yeh Gastroenterology median Middle half National median
2019 $2,173 $417 $126–$1,100 $163
2020 $948 $224 $74–$624 $114
2021 $1,733 $352 $106–$1,054 $132
2022 $2,002 $448 $129–$1,270 $149
2023 $1,722 $533 $150–$1,390 $160
2024 $628 $605 $160–$1,606 $164
2025 $699 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,092 105 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,178 71 payments
  3. Janssen Biotech, Inc. $971 47 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $885 45 payments
  5. Nestle HealthCare Nutrition Inc. $826 44 payments
  6. Celgene Corporation $773 32 payments
  7. Pfizer Inc. $407 20 payments
  8. Gilead Sciences, Inc. $345 13 payments
  9. Madrigal Pharmaceuticals $320 10 payments
  10. Novo Nordisk Inc $320 7 payments
  11. Other $1,788 84 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,782 475 payments
  2. Education $122 3 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,160 70 payments
  2. STELARA $971 47 payments
  3. ZEPOSIA $773 32 payments
  4. ZENPEP $721 39 payments
  5. HUMIRA $715 41 payments
  6. RINVOQ $461 13 payments
  7. ENTYVIO $396 22 payments
  8. XELJANZ $333 15 payments
  9. MAVYRET $331 18 payments
  10. CREON $302 15 payments
  11. Other $4,189 192 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

478 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record